|
|||||
|
|
Assessing the impact of the Australia-United States Free Trade Agreement on Australian and global medicines policy |
|
| Authors: | |
| Institution: | (1) Globalisation and Health Project, Centre for Governance of Knowledge and Development Regulatory Institutions Network Australian National University, Acton, Canberra, ACT, Australia;(2) Medical School and Law Faculty, The Australian National University, Acton, Canberra, ACT, Australia;(3) Newcastle Institute of Public Health, University of Newcastle, Newcastle, New South Wales, Australia;(4) Clinical Pharmacology, School of Medical Practice and Population Health, University of Newcastle, Newcastle, New South Wales, Australia;(5) Centre for Regulation and Market Analysis, University of South Australia, Adelaide, South Australia, Australia |
| Abstract: | On 1 January 2005, a controversial trade agreement entered into force between Australia and the United States. Though heralded by the parties as facilitating the removal of barriers to free trade (in ways not achievable in multilateral fora), it also contained many trade-restricting intellectual property provisions and others uniquely related to altering pharmaceutical regulation and public health policy in Australia. The latter appear to have particularly focused on the world-respected process of federal government reimbursement after expert cost-effectiveness evaluation, popularly known as the Pharmaceutical Benefits Scheme ('PBS'). It remains uncertain what sort of impacts – if any – the Australia-United States Free Trade Agreement ('AUSFTA') will have on PBS processes such as reference pricing and their important role in facilitating equitable and affordable access to essential medicines. |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |